Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases

European Journal of Surgical Oncology

Volumn 37, Issue 11, 2011, Pages 971-977

  Classe, J M ^a   Jaffre, I ^a   Frenel, J S ^a   Bordes, V ^a   Dejode, M ^a   Dravet, F ^a   Ferron, G ^b   Marchal, F ^c   Berton Rigaud, D ^a   Loussouarn, D ^d   Campion, L ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d CHU de Nantes   (France)

Author keywords

Ovarian cancer; Prognostic factor; Relapse; Surgery; Survival

Indexed keywords

PLATINUM;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CLINICAL FEATURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 80053623186     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.08.138     Document Type: Article

References (35)

1. C. Hill, and F. Doyon The frequency of cancer in France in year 2002, and trends since 1968 Bull Cancer 93 1 2006 7 11 (Pubitemid 43265693)
2. S.A. Cannistra Cancer of the ovary N Engl J Med 351 24 2004 2519 2529
3. A. du Bois, M. Quinn, and T. Thigpen 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl. 8 2005 viii7 viii12
4. W.E. Winter 3rd, G.L. Maxwell, and C. Tian Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 24 2007 3621 3627 (Pubitemid 47372600)
5. I. Skirnisdottir, and B. Sorbe Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma Int J Oncol 30 3 2007 727 734
6. P.Y. Roland, M.N. Barnes, and S. Niwas Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens Gynecol Oncol 68 2 1998 178 182 (Pubitemid 28150771)
7. P. Viens, T. Petit, and A. Yovine A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients Ann Oncol 17 3 2006 429 436 (Pubitemid 43329579)
8. M. Markman "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer? Gynecol Oncol 69 2 1998 91 92 (Pubitemid 28246990)
9. M.K. Parmar, J.A. Ledermann, and N. Colombo Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 9375 2003 2099 2106
10. M.M. Leitao Jr., S. Kardos, R.R. Barakat, and D.S. Chi Tertiary cytoreduction in patients with recurrent ovarian carcinoma Gynecol Oncol 95 1 2004 181 188 (Pubitemid 39286295)
11. R.E. Bristow, I. Puri, and D.S. Chi Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis Gynecol Oncol 112 1 2009 265 274
12. D.S. Chi, K. McCaughty, and J.P. Diaz Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma Cancer 106 9 2006 1933 1939 (Pubitemid 43673208)
13. R.E. Bristow, M. Peiretti, and M. Gerardi Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome Gynecol Oncol 114 2 2009 173 177
14. G. Ferrandina, M. Ludovisi, G. Corrado, V. Carone, M. Petrillo, and G. Scambia Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer Gynecol Oncol 109 2 2008 187 193
15. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
16. M.L. Berman Future directions in the surgical management of ovarian cancer Gynecol Oncol 90 2003 S33 S39
17. A.R. Munkarah, and R.L. Coleman Critical evaluation of secondary cytoreduction in recurrent ovarian cancer Gynecol Oncol 95 2 2004 273 280 (Pubitemid 39445861)
18. P. Harter, A. Bois, and M. Hahmann Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial Ann Surg Oncol 13 12 2006 1702 1710 (Pubitemid 44951480)
19. E.H. Tay, P.T. Grant, V. Gebski, and N.F. Hacker Secondary cytoreductive surgery for recurrent epithelial ovarian cancer Obstet Gynecol 99 6 2002 1008 1013 (Pubitemid 34621223)
20. R. Salani, A. Santillan, and M.L. Zahurak Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome Cancer 109 4 2007 685 691 (Pubitemid 46233229)
21. A. Munkarah, C. Levenback, and J.K. Wolf Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer Gynecol Oncol 81 2 2001 237 241 (Pubitemid 32424168)
22. A. Gadducci, P. Iacconi, S. Cosio, A. Fanucchi, R. Cristofani, and A. Riccardo Genazzani Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer Gynecol Oncol 79 3 2000 344 349
23. J. Bae, M.C. Lim, and J.H. Choi Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer J Gynecol Oncol 20 2 2009 101 106
24. L. Vaccarello, S.C. Rubin, and V. Vlamis Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response Gynecol Oncol 57 1 1995 61 65
25. T. Onda, H. Yoshikawa, T. Yasugi, M. Yamada, K. Matsumoto, and Y. Taketani Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection Br J Cancer 92 6 2005 1026 1032 (Pubitemid 40546664)
26. J.S. Berek, N.F. Hacker, L.D. Lagasse, R.K. Nieberg, and R.M. Elashoff Survival of patients following secondary cytoreductive surgery in ovarian cancer Obstet Gynecol 61 2 1983 189 193 (Pubitemid 13110698)
27. S.M. Eisenkop, R.L. Friedman, and N.M. Spirtos The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma Cancer 88 1 2000 144 153 (Pubitemid 30027690)
28. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 5 2002 1248 1259 (Pubitemid 34177431)
29. A. du Bois, and P. Harter The role of surgery in advanced and recurrent ovarian cancer Ann Oncol 17 Suppl. 10 2006 x235 x240
30. A. Fagotti, G. Ferrandina, and F. Fanfani Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma Am J Obstet Gynecol 199(6) 642 2008 e1 6
31. D.S. Chi, C.C. Franklin, and D.A. Levine Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach Gynecol Oncol 94 3 2004 650 654 (Pubitemid 39194456)
32. R.Y. Zang, Z.T. Li, and J. Tang Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100 6 2004 1152 1161 (Pubitemid 38325942)
33. C.C. Earle, D. Schrag, and B.A. Neville Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients J Natl Cancer Inst 98 3 2006 172 180 (Pubitemid 43205479)
34. R.E. Bristow, M.L. Zahurak, T.P. Diaz-Montes, R.L. Giuntoli, and D.K. Armstrong Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes Gynecol Oncol 115 3 2009 334 338
35. K.A. Donovan, P.G. Greene, J.L. Shuster, E.E. Partridge, and D.C. Tucker Treatment preferences in recurrent ovarian cancer Gynecol Oncol 86 2 2002 200 211 (Pubitemid 34953505)